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Abstract
Objective. To present the detection rates of Candida species in vaginal samples from patients visiting physicians.
Methods. The presence of C. albicans, C. glabrata, C. parapsilosis and C. tropicalis in 3978 vaginal swabs from patients in six
US states was detected by PCR ampliﬁcation.
Results. Candida DNA was detected in 33.1% of the population studied. Of the 1316 positive samples, 80.2% contained C.
albicans, 14.3% contained C. glabrata, 5.9% contained C. parapsilosis and 8.0% contained C. tropicalis. Comparing samples
by patients’ state of residence revealed an association with the detection of C. glabrata (p=0.029). Comparing samples by
patients’ age revealed a decrease in the overall detection of Candida (p50.001) and C. albicans (p50.001), concomitant
with an increase in the detection of C. glabrata (p50.001) and C. parapsilosis (p=0.025).
Conclusions. These results provide geographic- and age-speciﬁc data on four Candida species associated with vaginitis.
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Introduction
Candida species cause 20% to 25% of the cases of
infectious vaginitis, second only to the 40% to 50%
of cases caused by bacteria [1]. Candidal vaginitis
(CV) is marked by pruritis, soreness, a change in
discharge, dyspareunia, vulvar erythema, edema and
ﬁssures [1, 2]. The condition is rare before puberty
but by the age of 25 years, nearly 50% of all women
will have had at least one clinician-diagnosed episode
of CV [3,4]. The condition is less common in post-
menopausal women. Overall, it is estimated that 75%
of all women will experience an episode of CV in
their lifetime [1, 5].
Candida albicans accounts for 80% to 92% of all
cases of CV worldwide [1, 6]. Vaginal colonization
by non-albicans species is more common in im-
munodeﬁcient women. However, an increased
frequency of non-albicans Candida species, particu-
larly C. glabrata, C. parapsilosis and C. tropicalis, has
been reported in healthy women [7]. The widespread
use of azole antifungal drugs is postulated to have
promoted the shifting of vaginal colonization and
selection of more naturally resistant species, such as
C. glabrata [8–11].
We investigated the detection rate of four different
Candida species isolated from women in Florida
(FL), Georgia (GA), Louisiana (LA), New Jersey
(NJ), Pennsylvania (PA) and Texas (TX). The use of
rapid PCR-based assays for the speciﬁc detection of
C. albicans, C. glabrata, C. parapsilosis and C.
tropicalis allowed large-scale surveillance of the
results obtained from these vaginal samples. The
established PCR methods have high sensitivity and
speciﬁcity and have a shorter turn-around time in
comparison with current microscopy and culture
techniques[12]. This study, using the PCR method,
will provide detection data to help guide clinical
evaluation and therapy.
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Clinical samples
Between April and November 2003, vaginal swabs
from a total of 3978 women from FL, GA, LA, NJ,
PA, and TX were submitted to our laboratory for
Candida PCR testing. Tests were performed with
informed consent as ordered by the evaluating
physician following the guidelines of the laboratory’s
federal, state, and Clinical Laboratory Improvement
Amendments (CLIA) certiﬁcations. Patient anon-
ymity was strictly protected in accordance with the
federal Health Insurance Portability and Account-
ability Act (HIPAA) of 1996. Subjects were informed
of the results of the testing procedures. None of the
samples was accompanied by information regarding
the medical history or clinical presentation of the
participant. Only the woman’s state of residence and
age were obtained for the purposes of this retro-
spective study. The specimens were collected from a
vaginal sampling performed by the evaluating physi-
cian with a Cellmatics swab (BD, Sparks, MD,
USA), which was then placed in 2 ml of transport
medium (BD, Sparks, MD, USA). Upon receipt,
swabs were immediately processed for PCR analysis.
DNA extraction
Established procedures for DNA extraction were
used. In brief, swabs were thoroughly mixed in the
transport media contained within the transport vials;
470 ml of transport media was mixed with 25 mlo f
10% sodium dodecyl sulfate and 12 ml of freshly
prepared DNase-free proteinase-K (10 mg/ml), then
incubated for 2 h at 558C. DNA was extracted in
phenol:chloroform:isoamyl alcohol and recovered by
ethanol precipitation, pelleted, dried in a speed
vacuum, and re-suspended in 20 ml TE buffer.
Absorbance was monitored by 260/280 readings
with a spectrophotometer, and the DNA concentra-
tion was adjusted to 0.2 mg/ml before PCR analysis.
PCR analysis
The oligonucleotide primers used for species-speciﬁc
ampliﬁcation of Candida ribosomal DNA and reac-
tion conditions were previously described [12].
Primers were synthesized by Invitrogen (Carlsbad,
California) and puriﬁed by reverse-phase cartridge
chromatography. All PCR reactions were carried out
in 0.2-ml tubes using a T3 Thermocycler (Biometra,
Go ¨ttingen, Germany) with 1 mg of extracted DNA in
50 ml total volume. Thermocycling was performed as
follows: initial denaturation at 948C for 3 min,
followed by 40 cycles of 948C for 30 s, 588Ct o
628C for 30 s, and 728C for 30 s, with a ﬁnal
elongation at 728C for 10 min. PCR products were
analyzed by electrophoresis through a 2% agarose gel
containing 0.5 mg/ml ethidium bromide and UV
visualization using a MultiGenius gel documentation
and analysis system (Syngene, Frederick, MD,
USA). Positive controls were included in each PCR
experiment and consisted of C. albicans, C. glabrata,
C. parapsilosis and C. tropicalis (ATCC 14053, 2001,
22019 and 13803, respectively). Negative controls in
each experiment consisted of the substitution of
nuclease and pyrogen-free water for DNA; 100%
speciﬁcity and 100% sensitivity of these PCR
ampliﬁcations were previously determined [12].
Additionally, PCR ampliﬁcations with each primer
pair exhibited no cross-reactivity among the four
Candida species or a panel of genomic DNA
extracted from 35 known bacterial, fungal, and viral
pathogens (data not shown).
Protection against contamination
DNA extraction and PCR were performed under
sterile conditions and in separate rooms. Water for
all experiments was nuclease- and pyrogen-free.
Microcentrifuge tubes were sterilized in an auto-
clave and UV-irradiated. Nuclease-free PCR tubes
(Costar, Corning, NY, USA) were UV-irradiated.
Pipettes were used solely with ﬁlter tips for PCR.
PCR reactions were prepared in a UV-irradiated
biological safety cabinet (Labconco, Kansas City,
MS, USA).
Statistical analysis
Chi-square and chi-square for trend tests were used
for comparisons as noted; northeastern and southern
geographic regions were determined by 2000 US
census bureau mapping. Unpaired t tests compared
means and Spearman r tests determined correlations
as noted. A two-tailed p value of less than 0.050 was
considered to be signiﬁcant. All tests were performed
using GraphPad Instat version 3.0b for Macintosh
(GraphPad Software, San Diego, CA, USA).
Results
Characteristics of the study population
A total of 3978 samples originating from women
residing in FL, GA, LA, NJ, PA and TX were
included in the present study (distribution shown in
Table I). These states represent those from which
evaluating physicians routinely send vaginal swabs to
our laboratory for Candida PCR testing. Participants’
ages at the time of sample collection ranged from 12
to 97 years. The mean age was 34.5+13.0 years.
Data were divided into ﬁve age groups, containing
women of ages 12 to 25 years, 26 to 35 years, 36 to
64 J. P. Trama et al.45 years, 46 to 55 years and 55 to 97 years
(distribution shown in Table II).
Geographic differences in detection rate of
Candida
Table I summarizes the results obtained by the
Candida PCR test categorized by the subjects’ state
and region of residence. Chi-square analysis revealed
no signiﬁcant association of the overall positivity rate
(determined by detection of any of the four Candida
species) or detection rates (determined out of all
samples in a group) of C. albicans, C. parapsilosis, C.
tropicalis and multiple colonizing Candida species
with the state of residence. However, the detection of
C. glabrata was determined to be signiﬁcantly
associated with the state of residence, with the lowest
detection rate in PA (2.5%) and the highest in TX
(5.7%). Grouping the states into two regions,
northeast (NJ and PA) and south (FL, GA, LA,
and TX), revealed a signiﬁcant association of the
detection rate of C. glabrata and the region of
residence (p=0.032). The detection rate was 3.1%
(95% CI, 2.0% to 4.7%) in the northeast and 5.1%
(95% CI, 2.5% to 5.9%) in the south, with a
difference of 2.0+0.87%.
Age differences in detection rate of Candida
Table II summarizes the results obtained by the
Candida PCR test categorized by participants’ age.
Chi-square analysis revealed no signiﬁcant associa-
tion of the detection rates of C. tropicalis and multiple
colonizing Candida species with age. However, the
overall positivity rate and the detection of C. albicans,
C. glabrata and C. parapsilosis were determined to be
signiﬁcantly associated with the subject age groups:
as age increased, the overall positivity rate and the
detection rate of C. albicans gradually decreased
concomitant with an increase in the detection rate of
C. glabrata and C. parapsilosis. Each of these changes
was determined to have a signiﬁcant linear trend
among the sequential age groups by chi-squared tests
for trend.
In that the increase in the detection rate of C.
glabrata was associated with increase in age, the
geographical differences in the detection rate of C.
glabrata might reﬂect the age distribution in each
state. In Table III, the mean age and standard
deviation for each state and for the northeast and
south regions are shown. A Spearman r test showed
no signiﬁcant correlation between the mean age and
the detection rate of C. glabrata in each state
Table I Distribution of samples and detection rate of Candida species by subjects’ state of residence.
Region State Samples Positive (%
a)
C.alb.
(%
a;%
b)
C.glab.
(%
a;%
b)
C.para.
(%
a;%
b)
C.trop.
(%
a;%
b)
Multiple
(%
a;%
b)
Northeast NJ 570 194 (34.0) 163 (28.6;84.0) 19 (3.3;9.8) 13 (2.3;6.7) 10 (1.8;5.2) 10 (1.8;5.2)
PA 163 49 (30.1) 41 (25.2;83.7) 4 (2.5;8.2) 3 (1.8;6.1) 5 (3.1;10.2) 4 (2.5;8.2)
South FL 1286 419 (32.6) 323 (25.1;77.1) 69 (5.4;16.5) 30 (2.3;7.2) 36 (2.8;8.6) 34 (2.6;8.1)
GA 362 117 (32.3) 100 (27.6;85.5) 11 (3.0;9.4) 6 (1.7;5.1) 8 (2.2;6.8) 8 (2.2;6.8)
LA 189 51 (27.0) 40 (21.2;78.4) 5 (2.7;9.8) 3 (1.6;5.9) 5 (2.7;9.8) 2 (1.1;3.9)
TX 1408 486 (34.5) 389 (27.6;80.0) 80 (5.7;16.5) 22 (1.6;4.5) 41 (2.9;8.4) 45 (3.2;9.3)
Total 3978 1316 (33.1) 1056 (26.6;80.2) 188 (4.7;14.3) 77 (1.9;5.9) 105 (2.6;8.0) 103 (2.6;7.8)
p Value
c 0.344 0.252 0.029 0.741 0.754 0.345
For each individual species, samples with multiple species are included.
aPercentage of the number of samples from each row category;
bpercentage of the number of positives from each row category;
cthe two-tailed p value is calculated from chi-square testing of column data,
excluding the total.
Table II Distribution of samples and detection of Candida species by subjects’ age in years.
Group Age Samples Positive (%
a)
C.alb.
(%
a;%
b)
C.glab.
(%
a;%
b)
C.para.
(%
a;%
b)
C.trop.
(%
a;%
b)
Multiple
(%
a;%
b)
I 12–25 1116 417 (37.4) 349 (31.3;83.7) 44 (3.9;10.6) 20 (1.8;4.8) 35 (3.1;8.4) 30 (2.7;7.2)
II 26–35 1311 441 (33.6) 378 (28.8;85.7) 41 (3.1;9.3) 20 (1.5;4.5) 31 (2.4;7.0) 28 (2.1;6.4)
III 36–45 847 264 (31.2) 205 (24.2;77.7) 51 (6.0;19.3) 16 (1.9;6.1) 19 (2.2;7.2) 24 (2.8;9.1)
IV 46–55 413 119 (28.8) 80 (19.4;67.2) 31 (7.5;26.1) 8 (1.9;6.7) 8 (1.9;6.7) 8 (1.9;6.7)
V 56–97 291 75 (25.8) 44 (15.1;58.7) 21 (7.2;28.0) 13 (4.5;17.3) 12 (4.1; 16.0) 13 (4.5; 17.3)
p Value
c 50.001 50.001 50.001 0.025 0.262 0.193
p Value
d 50.001 50.001 50.001 0.025 0.886 0. 319
For each individual species, samples with multiple species are included.
aPercentage of the number of samples from each row category;
bpercentage of the number of positives from each row category;
cthe two-tailed p value is calculated from chi-square testing of column data;
dthe two-tailed p value is calculated from chi-square for trend test of column data.
Detection rates of Candida spp. in vaginal samples 65(p=0.497). However LA, which had the lowest
average age, also had the lowest detection rate of C.
glabrata. When samples were grouped by region, an
unpaired t test showed the average subject age was
signiﬁcantly greater in the northeast (p50.001, 95%
CI 1.0 to 3.0 years). Therefore, the geographical
differences in the detection rate of C. glabrata were
probably not due to biases in the age distribution of
the study populations.
Discussion
In this retrospective study, we analyzed PCR-based
tests performed at our facility to estimate the
detection rate of Candida species present in vaginal
samples from patients of diverse geographic areas
and various ages within the USA. The analysis
beneﬁts from the large-scale surveillance of samples
by sensitive and speciﬁc PCR methods. However, it
is recognized that the data do not represent a random
sampling within these states and age groups, but
rather a more speciﬁc population of women visiting
submitting physicians for aid in diagnosis of abnor-
mal conditions.
Although there was no signiﬁcant association
between the subjects’ region of residence and the
overall positivity rate for Candida, there was a
signiﬁcant association with the detection of C.
glabrata. The 1.6-fold increase in the detection of
C. glabrata in the south region suggested that
regional differences in study population might favor
colonization or infection by this particular species.
Since age distribution in each state was probably not
an attributing factor, lifestyle, behavior, and environ-
mental conditions might be associated with the
differences in the detection rate of C. glabrata.
However, further investigation is necessary to
directly address this observation and discriminate
unanticipated subject selection biases.
Our results analyzing the detection of Candida in
vaginal swabs by patients’ age were in agreement
with previous reports of clinician diagnosis of CV [1,
3–5]. We showed that women younger than 26 years
of age (Table 2, Group I) had the highest rate of
detectable Candida, and that this rate was lowest
after the age of 56 years (Table 2, Group V). In
addition, our data identifying the Candida species
revealed interesting trends associated with partici-
pants’ age. As the overall detection of Candida
decreased with age, changes in the distribution of
individual species occurred. Although the dominant
Candida species found in vaginal swabs remained C.
albicans, the detection rate of C. glabrata increased
2.1-fold in the age group 36 to 45 years (Table 2,
Group III) and continued to increase in the age
groups 46 to 55 and 56 to 97 years (Table 2, Groups
IV and V). Also, the rate of C. parapsilosis increased
2.6-fold in the age group 56 to 97 years (Table 2,
Group V). It could be postulated that these changes
in distribution were related to selection of resistant
species by widespread use of azole-based anti-fungal
drugs (particularly in the case of C. glabrata) [8, 9,
13], hormonal changes due to menopause and
estrogen treatments [14, 15], the effects of aging on
protective immune responses [16, 17] and prolonged
stays in hospital [11]. These factors might change the
vaginal environment and the characteristics of
vaginal ﬂoral to favor the growth and virulence of
non-albicans species, or might increase subject
exposure to non-albicans species.
Finally, of interest is the overall detection rate of
non-albicans species, particularly C. glabrata, which
is more naturally resistant to common azole-based
antifungal drugs than C. albicans [13, 18]. One
recent worldwide study comparing the susceptibil-
ities of Candida species to ﬂuconazole indicated that,
in 2001, 0.6% of C. albicans isolates from genitalia
were resistant, compared with 30.7% of C. glabrata
isolates [19]. Considering that our results showed a
9.3% non-albicans species detection rate and a 4.7%
C. glabrata detection rate, current routine diagnostic
tests that only identify C. albicans might be inade-
quate. It is important to include non-albicans species
in testing vaginal samples to accurately diagnose
abnormal conditions, as well as assist physicians in
choosing drug treatment for CV and to monitor the
trends of resistance.
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